Swift Transportation Co. (NYSE: SWFT) said late last evening that its net income in the fiscal first quarter jumped more than three times as revenue improved across all segments while favorable comparables (fewer debt extinguishment charges compared to year earlier quarter) and slight decline in fuel prices also boosted the bottom line.
Continue reading Swift Transportation Beats Q1 Estimates (SWFT)
Shares movie streaming and DVD rental Company Netflix Inc. (NASDAQ: NFLX) climbed about 5.60% by afternoon trade after analysts at at B. Riley & Co upgraded the stock from “sell” to “buy” rating, and boosted the price target on the stock to $165 from $90. Earlier on April 15, another equity research firm BS AG initiated the coverage of the stock with a “buy” rating and set a price target of $250.0 a share.
Continue reading Major Movers on April 22; NFLX, BIIB, SIX, NVR, HAL
Oilfield services provider, Halliburton Company (NYSE: HAL) said on Monday that it swung into fiscal first-quarter loss as it set aside a big onetime $637 million litigation charges, linked to the Deepwater Horizon disaster.
Continue reading Halliburton Tops Estimates, Shares Gain (HAL)
Restoration Hardware Holdings Inc. (NYSE: RH) skyrocketed about 20% by midday trading after the home furnisher, late last evening reported very strong fiscal fourth quarter results and provided upbeat guidance on the fiscal first quarter and full-year. The Company reported earnings of 64 cents a share, while analysts’ consensus estimate was for earnings of 60 cents a share, according to a data compiled by Thomson Reuters. Net revenue surged about 30% to $398.05 million in the fiscal fourth quarter from $305.24 million, in the same quarter of last year. Analysts’ consensus forecast was for revenue of $390.86 million. Same-store-sales soared 26%. For the fiscal first quarter, the Company expects revenue growth 28% to 31%. For the full fiscal year, it expects revenue growth of 19% to 22%.
Continue reading Major Movers on April 19; RH, VRTX, IBM, ACTG, MSFT, EFII
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) skyrocketed 52.26% during afterhours trading on Thursday after the company said that mid-stage clinical trial of its unbranded treatment called VX-661 showed significant improvements in lung functions among adults.
Continue reading Vertex Pharmaceuticals Shares Soar over VX-661 Mid-Stage Results (VRTX)
Chipotle Mexican Grill Inc. (NYSE: CMG) reported fiscal first-quarter results on Thursday which showed profit jumping 22% thanks to higher customers traffic, offsetting rising food price inflation.
Continue reading Chipotle Comfortably Beats Q1 Earnings Expectations, Maintains Outlook (CMG)
Shares of Theravance Inc. (NASDAQ: THRX) rallied about 15% by afternoon trade after a federal advisory panel on Wednesday said that proposed lung treatment drug, Breo Ellipta, jointly developed by GlaxoSmithKline PLC and Theravance was not only effective but also safe and confirmed that it will approve the product . Breo Ellipta, which is meant to treat chronic obstructive pulmonary disease or COPD, is once-a-day inhalation drug.
Continue reading Major Movers on April 18; THRX, CLB, SNDK, EBAY, MS
U.S. equity market kicked off 2013 on a strong note, with all three benchmark indexes posting significant gains in the first quarter. The rally was driven mainly by an improving outlook for the U.S. economy. The big question is can the rally continue in the second quarter?
Although PepsiCo Inc. (NYSE: PEP) reported that its fiscal first-quarter earnings declined 4.6% due to restructuring costs and increased spending on advertising and charge linked to devaluation of Venezuelan currency, shares of the beverage Company climbed on Thursday as adjusted earnings and revenue edged past Street’s estimate.
Continue reading PepsiCo Posts Strong Q1 Earnings, Maintains Outlook (PEP)
Shares of Alkermes Plc (NASDAQ: ALKS) skyrocketed 16% in regular trading hours on Wednesday after the biopharmaceutical company said that its stage-2 clinical trial on the unbranded drug called ALKS 5461 showed that it was effective in treating patients suffering from major depressive disorder (MDD). In a statement, the Company said that study conducted among 142 patients showed that the treatment ALKS 5461, which is a one-a day, non-addictive oral medicine, “significantly reduced” depressive symptoms among patients.
Continue reading Shares of Alkermes Soar on MDD Treatment Potential (ALKS)